Liver cancer
Conditions
Interventions
Observation group:No
Treatment group:Treatment of hepatic nodules
Sponsors
The Second Affiliated Hospital of Chongqing Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 100 Years
Inclusion criteria
Inclusion criteria: 1. Willing and able to sign informed consent; 2. Male or female, 18 <= age <= 75; 3. The diagnosis was in accordance with the 2019 guidelines for the diagnosis and treatment of chronic hepatitis B and received anti-HBV treatment for 48 weeks; 4. Imaging examination showed liver nodules or space-occupying lesions (any imaging examination of abdominal color Doppler ultrasound, CT and MRI), and imaging examination could not determine the benign and malignant of the lesions; 5. The estimated survival time is more than half a year; 6. Peripheral blood cfDNA gene screening is high risk; 7. Have full civil capacity.
Exclusion criteria
Exclusion criteria: 1. Diagnosis of primary liver cancer or supported by the following evidence: elevated alpha-fetoprotein (AFP) (>= 100 uG/L) lasting for more than 3 months or liver imaging showed clear liver cancer nodules in the liver; 2. Have a history of malignant tumors within 5 years before the screening, except for specific cancers cured by surgical resection (such as basal cell skin cancer); 3. Current or previous history of major diseases that may interfere with personal treatment, evaluation, or compliance. Major diseases are 25 major diseases specified by the CIRC; 4. Combined with HCV, HIV, HDV, or other infectious diseases; 5. Severe pulmonary disease, severe heart disease, diabetes, or genetic metabolic diseases. 6. Psychiatric hospitalization, attempted suicide and/or temporary disability due to mental illness in the past five years; 7. Combined with autoimmune liver disease, alcoholic liver disease, and drug-induced liver injury; 8. Pregnant or lactating women; 9. The researcher believes that it is not suitable to participate in this experiment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Time from enrollment to development of liver cancer; | — |
Countries
China
Contacts
Public ContactDazhi Zhang
The Second Affiliated Hospital of Chongqing Medical University
Outcome results
None listed